Title

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke
Comparison of Magnesium Chloride Infusions Versus Placebo Administered Concomitantly With 100% Oxygen Given to Patients Who Have Residual Muscle Weakness From a Stroke That Occurred Three Months to Four Years Ago
  • Phase

    Phase 2/Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    magnesium ...
  • Study Participants

    81
The purpose of this study is to evaluate the effect of six intravenous (IV) infusions of magnesium chloride versus placebo in patients who have residual muscle weakness from a stroke that occurred three months to four years ago.
The hypothesis being tested is that these six treatments will improve muscle weakness and lead to an improvement in functioning/activities of daily living as measured by the 100-point Barthel index, three months after their last treatment versus their baseline measure, and that the mean difference between the treatment and placebo groups of patients will be at least three points in this index.
Study Started
Apr 30
2009
Primary Completion
May 31
2010
Study Completion
Jul 31
2010
Last Update
May 25
2012
Estimate

Drug Magnesium Chloride

An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen

Drug Placebo

A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent

Magnesium infusion in patients breathing 100% oxygen Experimental

Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).

Placebo infusion Placebo Comparator

The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.

Criteria

Inclusion Criteria:

Subjects of either sex above 18 years of age
Documented history of stroke 3 months to four years ago
Subjects may have had two or more strokes
Must have residual muscle weakness with a 25% or greater difference in strength between the right and left sides of the body
Must be assessed as a 2 or 3 on the Modified Rankin Scale
Must have a Barthel score at or below 85

Exclusion Criteria:

Any traumatic brain injury or other brain injury apart from stroke
Renal insufficiency or renal failure
Any medical or physical condition that would interfere with the measurements to be conducted
Any physical therapy in a facility outside their home within three days of screening
No Results Posted